Inactive Instrument

Seagen Inc.

Equities

SGEN

US81181C1045

Biotechnology & Medical Research

Seagen to Report First Quarter 2023 Financial Results on April 27, 2023

April 10, 2023 at 07:22 am EDT

BOTHELL - Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023.

Given the recently announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call.

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.

Contact:

Douglas Maffei

Tel: (425) 527-4881

Email: dmaffei@seagen.com

Latest news about Seagen Inc.

Takeover rumors send Morphosys to high since July 2021	Feb. 05	DP
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P TMI Index	Dec. 18	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Global BMI Index	Dec. 18	CI
Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev	Dec. 15	DJ
Pfizer: dividend increases, stock rebounds	Dec. 15	CF
Euphoria subsides for Triple-Witching Day	Dec. 15
ANALYST RECOMMENDATIONS : Adobe, Blackrock, Roblox, Snap, US Bancorp...	Dec. 15
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	Dec. 15	MT
Seagen Inc.(NasdaqGM:SGEN) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ-100 Index	Dec. 15	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index	Dec. 15	CI
Pfizer, Inc: A cycle for nothing?	Dec. 14
Pfizer Completes $43 Billion Acquisition of Seagen	Dec. 14	MT
Pfizer: Seagen acquisition now complete	Dec. 14	CF
Seagen Inc. Announces Management Changes	Dec. 14	CI
Seagen Inc. Announces Cessation of David R. Epstein as Chief Executive Officer	Dec. 14	CI
Seagen Inc. Announces Cessation of Todd E. Simpson as Chief Financial Officer	Dec. 14	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ Composite Index	Dec. 14	CI
Pfizer Inc. completed the acquisition of Seagen Inc. from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.	Dec. 13	CI
Pfizer shares sink after it resets 2024 COVID expectations	Dec. 13	RE
Sector Update: Tech Stocks Rise Late Afternoon	Dec. 13	MT
Sector Update: Tech Stocks Mixed Wednesday Afternoon	Dec. 13	MT
Global markets live: BAE Systems, Amazon, Take-Two, Shell, Pfizer...	Dec. 13
Pfizer shares slide as 2024 revenue outlook underwhelms	Dec. 13	AN

Chart Seagen Inc.

Duration

Period

More charts

Company Profile

Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).

Sector

Biotechnology & Medical Research

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research